Atherosclerosis 05/09/2002 By David Ball
Atorvastatin can significantly reduce postprandial plasma concentrations of triglyceride-rich lipoproteins (TRLs) in postinfarction patients with combined hyperlipidaemia, say Swedish researchers. Daily 40 mg doses of atorvastatin, a 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, was found to reduce postprandial plasma concentrations of all TRLs in patients with premature coronary artery disease. This investigation at the Atherosclerosis Research Unit and Department of Cardiology, Karolinska Hospital, Stockholm, Sweden, enrolled 16 middle-aged men with previous myocardial infarction and combined hyperlipidaemia. The researchers note that increased and extended postprandial lipaemia is implicated in coronary and carotid artery disease. Subjects were randomised in a double-blind, crossover design and were given atorvastatin 40 mg or placebo once daily for eight weeks. Chylomicron remnant and very low density lipoprotein (VLDL) particle concentrations were measured in the fasting state and after a mixed meal intake by the apolipoprotein (apo) B-48 and B-100 contents determined in subfractions of TRLs. Significant reductions in fasting plasma concentrations of VLDL cholesterol, LDL cholesterol and VLDL triglycerides were seen in the atorvastatin group. Compared with baseline, atorvastatin treatment increased high density lipoprotein (HDL) cholesterol by 19 percent.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!